Cleo Diagnostics Ltd has released a press release.
COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from CLEO Diagnostics
- COV Appoints CRO to Manage US Ovarian Cancer Clinical Trials
- CLEO Appoints Partner to Commence U.S. Market Access Program
- Peer-Review Supports CLEOs Ovarian Cancer Detection Tech
- Cleo Completes Design Transfer
- Completion of First Triage Test Clinical Validation Study
Later from CLEO Diagnostics
- Cleo Commences US Regulatory Process with FDA
- CLEO Selects U.S. Clinical Trial Sites
- Appendix 4E and 2024 Annual Report
- Cleo Commences U.S. Clinical Trials
- The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics